Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-817 open-label extension study in adults with focal onset seizures
2026-526361-15-00Phase 2Authorised
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Oct 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of Huperzine A in Focal onset seizure, sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Incidence of treatment-emergent adverse events, Change from baseline in clinical laboratory test results and 3 more. Planned start Oct 2026; status: authorised.
02
Drugs
Huperzine A
03
Conditions
Focal onset seizure
Beyond the preview
Go deeper on 2026-526361-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526361-15-00.